Images List Premium Download Classic

Hyperlipidemia

Hyperlipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway
Temple University-of The Commonwealth System Of Higher Education
January 18, 2018 - N°20180015152

The present invention provides compositions and methods for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including but not limited to cardiovascular diseases and inflammatory disorders.
Isoquinoline derivatives as mgat2 inhibitors
Merck Sharp & Dohme Corp.
January 11, 2018 - N°20180009796

The compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4...
Warner-lambert Company Llc
January 11, 2018 - N°20180009748

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptatonic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state ...
Hyperlipidemia Patent Pack
Download + patent application PDFs
Hyperlipidemia Patent Applications
Download + Hyperlipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hyperlipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for treatment of hyperglycemia and hyperlipidemia
December 28, 2017 - N°20170368077

Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin k. Also provided is a method of enhancing protein expression ratio of phospho-5′ adenosine monophosphate-activated protein kinase (phospho-ampk) to total ...
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
December 14, 2017 - N°20170355994

The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting the angptl3 gene, as well as methods of inhibiting expression of angptl3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsrna compositions.
Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia ...
Althera Laboratories Ltd
December 14, 2017 - N°20170354604

Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.
Hyperlipidemia Patent Pack
Download + patent application PDFs
Hyperlipidemia Patent Applications
Download + Hyperlipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hyperlipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia ...
Althera Laboratories Ltd
November 30, 2017 - N°20170340569

The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same area under curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and ...
Bmp inhibitors and methods of use thereof
November 23, 2017 - N°20170334918

The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may ...
Methods for treating patients with familial hypercholesterolemia
November 02, 2017 - N°20170312359

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both hefh and hofh. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angptl3 in combination with a therapeutically effective amount of a ...
Compositions and methods for inhibiting bmp
University Of Houston System
October 26, 2017 - N°20170305883

The present invention provides small molecule inhibitors of bmp signaling and compositions and methods for inhibiting bmp signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as ...
Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ...
October 19, 2017 - N°20170296539

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in ...
Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor
Regeneron Pharmaceuticals, Inc.
October 12, 2017 - N°20170291937

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Composition for preventing or treating hyperlipidemia
Hawon Pharm. Corporation
October 12, 2017 - N°20170290874

A pharmaceutical composition for preventing or treating hyperlipidemia includes a salvia miltiorrhiza extract, a crataegus pinnatifida extract, a polygonum multiflorum extract, and a ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and ldl-cholesterol and increasing the amount of hdl-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of ...
Hyperlipidemia Patent Pack
Download + patent application PDFs
Hyperlipidemia Patent Applications
Download + Hyperlipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hyperlipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Endorecherche, Inc.
October 12, 2017 - N°20170290847

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor ...
Use of dihydrocholesterol
Nestec S.a.
October 05, 2017 - N°20170281650

The use of dihydrocholesterol (dhc) in low doses of up to 50 mg per kg of body weight to treat or prevention excess weight or obesity and/or hyperlipidemia, and/or a disorders associated with any of the foregoing, and a composition comprising dhc.
Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170275274

The present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273966

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273965

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
Dezima Pharma B.v.
September 21, 2017 - N°20170267640

The present invention relates to a process for the preparation of synthetic intermediates which may be used in the preparation of tetrahydroquinoline derivatives, which derivatives have an inhibitory activity against cholesteryl transfer protein (cetp), show effects of increasing hdl cholesterol level and decreasing ldl cholesterol level, and can be used for the treatment and/or prevention of diseases such as ...
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
The Trustees Of The University Of Pennsylvania
September 14, 2017 - N°20170258776

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages ...
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an ...
Regeneron Pharmaceuticals, Inc.
September 07, 2017 - N°20170253666

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Loading